A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2734 participants.
Also called NCT06065540
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,734 participants
- Sponsor
- Registry
-
NCT06065540 -
2022-502678-18
-
- Other papers using this trial's data
- Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Denmark, Finland, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Poland, Romania, Serbia, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Taiwan, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT06065540. Randomized; quadruple masking; primary purpose treatment. Start 2023-09-27 (actual); primary completion 2025-11-19 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
- Acronym
- REIMAGINE 2
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Cagrilintide
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo cagrilintide
- Intervention (Drug)
- Placebo semaglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct06065540- Content hash
2f697637255f249d7d9b450db7fc7ac01e38233d9f30361793711afc278f4e92